<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

1 min read

Gene Therapy for Rare Disorders 2023

Gene Therapy for Rare Disorders 2023

Date: March 20-23, 2023

Location: Sheraton Boston Hotel, Boston, MA - Directions

Event Website: https://genetherapy-conference.com/

 

Join us for our live presentation!

Silvia Ungari, Upstream Development Senior Scientist at AGC Biologics, will be presenting From Process Development to Achieving High Quality GMP Vectors.  We hope you'll join us at this amazing event to explore how we can create safer, more efficacious, and more accessible gene therapies for rare disorders.

Click the link above to get all the details. 

 

REQUEST A MEETING

You can also reach out directly to our experts attending the Symposium

Raghu Malapaka
Sr. Director, Business Development - Cell & Gene Therapy
Email  me
Paul DiCandeloro
Sr. Director, Business Development
Email  me
Silvia Ungari
Upstream Development Senior Scientist
Email  me

Learn about our cell and gene therapy services 

Cell Therapy Production and Manufacturing

AGC Biologics’ cell therapy services support every stage of the product journey, from pre-clinical through commercialization. At our Milan and Longmont facilities, we can work with virtually any cell type – including Human Mesenchymal Stem Cells (hMSCs), Exosomes, CD34+, T-Cells, NK Cells, and more.  

Using the latest autologous and allogeneic methods, we help your products meet the exact specifications for patients in a clinical or commercial setting. 

Learn more about our overall cell therapy offering 

Viral Vector Production and Manufacturing 

AGC Biologics scientists have two decades of viral vector-based gene therapy expertise and specialize in adeno-associated viral vectors (AAV), lentiviral vectors (LVV), and retroviral vectors (RVV). Our sites in the U.S. and Italy have supported four commercial products. 

Our ready-to-use platform capabilities for AAV and LVV programs are built on cell factories and bioreactors using adherent and suspension processes, designed entirely in-house. 

Discover more about our viral vector services 

Plasmid DNA (pDNA) Materials 

To support your pDNA needs, AGC Biologics utilizes a customized process based on your specific plasmid and hosting system. We have extensive technical expertise in fermentation, purification, and analytics, and our highly experienced teams routinely manufacture GMP-grade pDNA materials. This work includes starting material for gene therapy, and viral vector manufacturing. 

Learn more about our Plasmid offering

Fill out the form below to request a meeting during the event

 

ESGCT 30th Annual Congress, October 24-27

ESGCT 30th Annual Congress, October 24-27

CPHI Barcelona, October 24-26

CPHI Barcelona, October 24-26

BioJapan, October 11-13

BioJapan, October 11-13